LifeVantage Corporation (Nasdaq: LFVN) released its financial results for the fourth fiscal quarter and full year ended June 30, 2026. The health and wellness company focuses on products that activate optimal health at the cellular level. Revenue declined amid broader economic pressures and lower sales of key products.
Revenue reached $42.4 million. This marked a 23.1 percent drop from the prior year. The Americas region fell 24.8 percent. Asia/Pacific and Europe declined 16.9 percent. Net income per diluted share stood at $0.10. Adjusted earnings per share came in at $0.11. Adjusted EBITDA totaled $2.7 million.
Annual revenue was $182.6 million. This represented a 20.1 percent decrease year over year.Â
Americas revenue dropped 23.2 percent. Asia/Pacific and Europe fell 6.9 percent. Net income per diluted share was $0.40. Adjusted earnings per share reached $0.56. Adjusted EBITDA stood at $13.7 million.
Terrence Moorehead serves as President and Chief Executive Officer. He joined in August 2026 after leading Nature’s Sunshine Products. He expressed strong confidence in the company’s science-backed platform and debt-free balance sheet. Moorehead plans to strengthen the brand. He will build a more relevant consumer proposition and drive operational excellence with urgency.
LifeVantage traces its roots to 1988 under earlier names. It became LifeVantage Corporation in 2006. The firm shifted from retail to direct sales in 2009. It listed on Nasdaq in 2012. Headquarters are in Lehi, Utah. Major institutional holders include Capital Management Corporation. The company remains publicly traded and debt-free.
LifeVantage pioneers nutrigenomics. This science studies how nutrition activates genes for better health. Flagship products include the Protandim family. Other offerings feature TrueScience Liquid Collagen, MindBody GLP-1 System, AXIO energy mixes, and Petandim for dogs. The company acquired LoveBiome in October 2025. This added the P84 gut health activator.
Cash from operations totaled $10.2 million in fiscal 2026. Cash and equivalents stood at $14.9 million at year-end. The company holds no debt. It repurchased about 336,000 shares for $2.0 million. A $58.5 million balance remains under the existing share repurchase program.
The company did not issue formal guidance for fiscal 2027. This follows the recent CEO transition. Leadership aims to leverage strong gross margins and competitive advantages. Focus remains on long-term growth through science-backed products and operational improvements. For more information, visit www.lifevantage.com.
There are no reviews yet. Be the first one to write one.
